Drugs with expired main patents

1. List of Abilify drug patents

ABILIFY's oppositions filed in EPO
ABILIFY Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 months ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(1 year, 4 months ago)

US8642600 OTSUKA Method of treating autism
Jan, 2022

(1 year, 4 months ago)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(3 years from now)

US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(1 year, 4 months ago)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(6 months from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(3 years from now)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(1 year, 16 days from now)

US8642760

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(2 months ago)

US8642600

(Pediatric)

OTSUKA Method of treating autism
Jul, 2022

(10 months ago)

US8580796

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(2 months ago)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Dec, 2024

(1 year, 6 months from now)

Do you want to check out ABILIFY patents from before 2022?

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 07 June, 2006

Treatment: Treatment of major depressive disorder (mdd); Treatment of irritability associated with autistic disorder; Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia; Acute tr...

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of ABILIFY before it's patent expiration?
More Information on Dosage

ABILIFY family patents

55

United States

36

China

17

Hong Kong

11

Canada

11

Japan

11

European Union

10

Poland

10

Norway

8

Spain

8

Denmark

8

Ukraine

8

Portugal

7

Argentina

7

Cyprus

6

Austria

6

Germany

6

Slovenia

5

Russia

5

Korea, Republic of

5

Taiwan

4

Israel

4

Georgia

3

Malaysia

3

Brazil

3

New Zealand

3

Peru

3

Mexico

3

Australia

3

Ecuador

3

South Africa

2

Lithuania

2

Hungary

1

Philippines

1

Singapore

1

Chile

1

Colombia

2. List of Abilify Mycite Kit drug patents

ABILIFY MYCITE KIT's oppositions filed in EPO
ABILIFY MYCITE KIT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 months ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(1 year, 4 months ago)

US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(1 year, 4 months ago)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(6 months from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(3 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(3 years from now)

US8945005 OTSUKA Controlled activation ingestible identifier
Aug, 2029

(6 years from now)

US8956288 OTSUKA In-body power source having high surface area electrode
Jul, 2029

(6 years from now)

US8547248 OTSUKA Implantable zero-wire communications system
Dec, 2030

(7 years from now)

US9268909 OTSUKA Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
Oct, 2033

(10 years from now)

US8674825 OTSUKA Pharma-informatics system
Apr, 2029

(5 years from now)

US8847766 OTSUKA Pharma-informatics system
Mar, 2030

(6 years from now)

US9444503 OTSUKA Active signal processing personal health signal receivers
Nov, 2027

(4 years from now)

US8545402 OTSUKA Highly reliable ingestible event markers and methods for using the same
Apr, 2030

(6 years from now)

US9433371 OTSUKA In-body device with virtual dipole signal amplification
Sep, 2029

(6 years from now)

US8114021 OTSUKA Body-associated receiver and method
Jun, 2030

(7 years from now)

US11229378 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jul, 2031

(8 years from now)

US9320455 OTSUKA Highly reliable ingestible event markers and methods for using the same
Dec, 2031

(8 years from now)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(1 year, 16 days from now)

US9119554 OTSUKA Pharma-informatics system
Dec, 2028

(5 years from now)

US9258035 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(5 years from now)

US8258962 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Nov, 2030

(7 years from now)

US9941931 OTSUKA System for supply chain management
Nov, 2030

(7 years from now)

US7978064 OTSUKA Communication system with partial power source
Sep, 2026

(3 years from now)

US8718193 OTSUKA Active signal processing personal health signal receivers
Dec, 2029

(6 years from now)

US8961412 OTSUKA In-body device with virtual dipole signal amplification
Nov, 2030

(7 years from now)

US9060708 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(5 years from now)

US9149577 OTSUKA Body-associated receiver and method
Dec, 2029

(6 years from now)

US10517507 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jun, 2032

(9 years from now)

US10441194 OTSUKA Ingestible event marker systems
Jul, 2029

(6 years from now)

US11476952 OTSUKA Pharma-informatics system
Apr, 2026

(2 years from now)

US11464423 OTSUKA In-body power source having high surface area electrode
Sep, 2030

(7 years from now)

Do you want to check out ABILIFY MYCITE KIT patents from before 2022?

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia; Acute treatment of manic and mixed episodes associated with bipolar i disorder; Method of using a tablet embedded w...

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

219

United States

61

Japan

58

China

46

European Union

34

Canada

32

Israel

30

Hong Kong

26

Korea, Republic of

26

Taiwan

18

Denmark

18

Australia

17

Spain

14

Malaysia

14

Brazil

14

Singapore

13

Ukraine

12

Portugal

12

Mexico

11

Poland

11

Russia

11

South Africa

10

Norway

8

Cyprus

7

Argentina

7

Slovenia

6

Austria

6

Germany

5

New Zealand

4

India

4

Peru

4

Georgia

4

Ecuador

3

Chile

2

Philippines

2

Lithuania

2

Hungary

1

Morocco

EA

1

EA

1

Costa Rica

1

Finland

1

Colombia

1

Tunisia

3. List of Addyi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7420057 SPROUT PHARMS Stable polymorph of flibanserin
Aug, 2022

(9 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227471 SPROUT PHARMS Treating sexual desire disorders with flibanserin
May, 2023

(22 days ago)

US9468639 SPROUT PHARMS Treating sexual desire disorders with flibanserin
Oct, 2022

(7 months ago)

US7151103 SPROUT PHARMS Method of treating female hypoactive sexual desire disorder with flibanserin
May, 2028

(4 years from now)

Do you want to check out ADDYI patents from before 2022?

Drugs and Companies using FLIBANSERIN ingredient

Market Authorisation Date: 18 August, 2015

Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)

Dosage: TABLET;ORAL

More Information on Dosage

ADDYI family patents

23

United States

10

European Union

5

China

4

Brazil

4

Argentina

4

Japan

4

Korea, Republic of

2

Spain

2

Austria

2

Malaysia

2

Denmark

2

Germany

2

Poland

YU

2

Yugoslavia

2

Canada

2

Ukraine

EA

2

EA

2

Norway

2

New Zealand

2

Croatia

2

Israel

2

Portugal

2

Mexico

2

Australia

2

Ecuador

2

South Africa

2

Slovenia

2

Hungary

1

Hong Kong

1

ME

1

Colombia

4. List of Amlodipine Besylate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6828339 SYNTHON PHARMS Amlodipine salt forms and processes for preparing them
Nov, 2022

(6 months ago)

Do you want to check out AMLODIPINE BESYLATE patents from before 2022?

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 27 September, 2007

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

AMLODIPINE BESYLATE family patents

3

United States

1

Netherlands

1

Argentina

1

Norway

1

Australia

1

European Union

5. List of Banzel drug patents

BANZEL Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6740669 EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Nov, 2022

(6 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6740669

(Pediatric)

EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
May, 2023

(17 days ago)

Do you want to check out BANZEL patents from before 2022?

Drugs and Companies using RUFINAMIDE ingredient

Market Authorisation Date: 14 November, 2008

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BANZEL before it's patent expiration?
More Information on Dosage

6. List of Beyaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6441168 BAYER HLTHCARE Stable crystalline salts of 5-methyltetrahydrofolic acid
Jul, 2022

(10 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7163931 BAYER HLTHCARE Compositions of estrogen-cyclodextrin complexes
Mar, 2022

(1 year, 2 months ago)

US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(6 years from now)

Do you want to check out BEYAZ patents from before 2022?

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 24 September, 2010

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

How can I launch a generic of BEYAZ before it's patent expiration?
More Information on Dosage

BEYAZ family patents

8

United States

3

Korea, Republic of

3

Australia

3

European Union

2

Spain

2

Denmark

2

Czech Republic

2

China

2

Canada

EA

2

EA

2

Japan

2

ME

2

Croatia

2

Israel

2

Slovenia

2

Hungary

1

Uruguay

IB

1

IB

1

Hong Kong

1

Austria

1

RS

1

Germany

1

Poland

YU

1

Yugoslavia

1

Brazil

1

Estonia

1

Ukraine

1

Argentina

1

Norway

1

New Zealand

1

Cyprus

1

Peru

1

Portugal

1

Taiwan

1

Mexico

1

Bulgaria

1

South Africa

1

Slovakia

1

Lithuania

7. List of Caprelsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42353 GENZYME CORP Quinazoline derivatives and pharmaceutical compositions containing them
Jun, 2022

(11 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642608 GENZYME CORP Quinazoline derivatives as VEGF inhibitors
Feb, 2022

(1 year, 3 months ago)

US8067427 GENZYME CORP Pharmaceutical compositions comprising ZD6474
Aug, 2028

(5 years from now)

Do you want to check out CAPRELSA patents from before 2022?

Drugs and Companies using VANDETANIB ingredient

Market Authorisation Date: 06 April, 2011

Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease

Dosage: TABLET;ORAL

More Information on Dosage

CAPRELSA family patents

10

United States

5

European Union

4

Korea, Republic of

3

Spain

3

Austria

3

Hong Kong

3

Denmark

3

Germany

3

China

3

United Kingdom

3

Brazil

3

Argentina

3

Norway

3

Portugal

3

Slovenia

2

Iceland

2

Poland

2

Russia

2

Canada

2

Ukraine

2

Japan

2

ME

2

New Zealand

2

Cyprus

2

Israel

2

Taiwan

2

Mexico

2

Australia

2

South Africa

1

Uruguay

1

Malaysia

1

Czech Republic

1

RS

1

Estonia

1

Croatia

1

Belgium

1

Bulgaria

1

Slovakia

1

Saudi Arabia

1

Luxembourg

1

Hungary

8. List of Chantix drug patents

CHANTIX Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7265119 PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Aug, 2022

(9 months ago)

US6890927 PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
May, 2022

(1 year, 25 days ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6890927

(Pediatric)

PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Nov, 2022

(6 months ago)

US7265119

(Pediatric)

PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Feb, 2023

(3 months ago)

Do you want to check out CHANTIX patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Feb 22, 2022
Pediatric Exclusivity (PED) Aug 22, 2022

Drugs and Companies using VARENICLINE TARTRATE ingredient

Market Authorisation Date: 10 May, 2006

Treatment: Aid to smoking cessation

Dosage: TABLET;ORAL

How can I launch a generic of CHANTIX before it's patent expiration?
More Information on Dosage

CHANTIX family patents

3

United States

2

Ecuador

1

Panama

IB

1

IB

1

Spain

1

Austria

1

Hong Kong

1

Dominican Republic

1

Malaysia

1

Iceland

1

Denmark

AP

1

AP

1

Czech Republic

1

Germany

1

Poland

1

China

YU

1

Yugoslavia

1

Brazil

1

Canada

1

Ukraine

1

Estonia

1

Morocco

1

Argentina

EA

1

EA

1

Norway

OA

1

OA

1

Japan

1

ME

1

New Zealand

1

Croatia

1

Korea, Republic of

1

Guatemala

1

Peru

1

Israel

1

Portugal

1

Taiwan

1

Georgia

1

Mexico

1

Australia

1

Costa Rica

1

Bulgaria

1

South Africa

1

Slovakia

1

Egypt

1

Tunisia

1

Slovenia

1

Hungary

1

European Union

9. List of Combigan drug patents

COMBIGAN's oppositions filed in EPO
COMBIGAN Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7642258 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 1 month ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320976 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 1 month ago)

US8133890 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 1 month ago)

US9770453 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 1 month ago)

US9907801 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 1 month ago)

US8354409 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 1 month ago)

US8748425 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 1 month ago)

US9907802 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 1 month ago)

US9474751 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 1 month ago)

US7030149 ALLERGAN Combination of brimonidine timolol for topical ophthalmic use
Apr, 2022

(1 year, 1 month ago)

US7323463 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Jan, 2023

(4 months ago)

Do you want to check out COMBIGAN patents from before 2022?

Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient

Market Authorisation Date: 30 October, 2007

Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of ...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of COMBIGAN before it's patent expiration?
More Information on Dosage

COMBIGAN family patents

21

United States

4

European Union

3

China

2

Mexico

1

Spain

1

Hong Kong

1

Denmark

1

Brazil

1

Canada

1

Norway

1

Japan

1

New Zealand

1

Korea, Republic of

1

Cyprus

1

Portugal

1

Taiwan

1

Australia

1

Ecuador

1

Slovenia

10. List of Dexilant drug patents

DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(3 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Mar, 2030

(6 years from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(4 months from now)

US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Mar, 2032

(8 years from now)

US8722084 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(4 months from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(2 years from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Sep, 2026

(3 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(4 years from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation
Aug, 2026

(3 years from now)

US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(10 months from now)

US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(a month from now)

US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Feb, 2027

(3 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Mar, 2027

(3 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Sep, 2030

(7 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(3 years from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(10 months from now)

Do you want to check out DEXILANT patents from before 2022?

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive ...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's patent expiration?
More Information on Dosage

DEXILANT family patents

35

United States

23

Japan

12

European Union

9

Korea, Republic of

8

Canada

7

Spain

7

Argentina

6

China

5

Denmark

5

Brazil

5

Cyprus

5

Portugal

5

Australia

4

Hong Kong

4

Malaysia

4

Taiwan

4

Mexico

3

Poland

3

Russia

3

Norway

3

New Zealand

3

Peru

3

Israel

3

Costa Rica

2

Singapore

2

South Africa

2

Slovenia

1

Austria

1

Germany

1

Morocco

OA

1

OA

1

Belgium

1

Chile

1

Colombia

1

Hungary

11. List of Dexilant Solutab drug patents

DEXILANT SOLUTAB's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(3 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(4 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(10 months from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules
Jul, 2028

(5 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(2 years from now)

US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation
Mar, 2029

(5 years from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(4 years from now)

US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(a month from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(3 years from now)

Do you want to check out DEXILANT SOLUTAB patents from before 2022?

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

30

United States

21

Japan

10

European Union

8

Argentina

7

Canada

7

Korea, Republic of

5

Spain

5

China

5

Brazil

5

Peru

5

Taiwan

5

Australia

4

Malaysia

4

New Zealand

4

Mexico

4

Costa Rica

3

Hong Kong

3

Denmark

3

Poland

3

Norway

3

Cyprus

3

Portugal

3

South Africa

2

Morocco

2

Chile

2

Israel

2

Slovenia

1

Uruguay

1

Austria

1

Dominican Republic

1

Germany

1

Ukraine

1

Singapore

EA

1

EA

OA

1

OA

1

Belgium

1

Georgia

1

Ecuador

1

Colombia

1

Tunisia

1

Hungary

12. List of Folotyn drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6028071 ACROTECH Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
Jul, 2022

(10 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8299078 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(2 years from now)

US7622470 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(2 years from now)

Do you want to check out FOLOTYN patents from before 2022?

Drugs and Companies using PRALATREXATE ingredient

Market Authorisation Date: 24 September, 2009

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of FOLOTYN before it's patent expiration?
More Information on Dosage

FOLOTYN family patents

12

United States

2

China

2

New Zealand

2

Korea, Republic of

1

Spain

1

Hong Kong

1

Austria

1

Denmark

1

RS

1

Germany

1

Poland

1

Brazil

1

Canada

1

Norway

1

Japan

1

ME

1

Croatia

1

Portugal

1

Mexico

1

Australia

1

South Africa

1

Slovenia

1

European Union

13. List of Fusilev drug patents

FUSILEV Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6500829 ACROTECH Substantially pure diastereoisomers of tetrahydrofolate derivatives
Mar, 2022

(1 year, 2 months ago)

Do you want to check out FUSILEV patents from before 2022?

Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient

Market Authorisation Date: 07 March, 2008

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of FUSILEV before it's patent expiration?
More Information on Dosage

14. List of Lexapro drug patents

LEXAPRO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6916941 ALLERGAN Crystalline composition containing escitalopram
Aug, 2022

(9 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7420069 ALLERGAN Crystalline composition containing escitalopram
Aug, 2022

(9 months ago)

US6916941

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram
Feb, 2023

(3 months ago)

US7420069

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram
Feb, 2023

(3 months ago)

Do you want to check out LEXAPRO patents from before 2022?

Drugs and Companies using ESCITALOPRAM OXALATE ingredient

Market Authorisation Date: 14 August, 2002

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of LEXAPRO before it's patent expiration?
More Information on Dosage

LEXAPRO family patents

4

Denmark

4

Japan

3

United States

2

Spain

2

Austria

2

Germany

2

China

2

Croatia

2

Portugal

2

European Union

1

Uruguay

1

Hong Kong

1

Malaysia

1

Turkey

1

Iceland

1

Poland

YU

1

Yugoslavia

1

Brazil

1

Canada

1

Ukraine

1

Morocco

1

Argentina

EA

1

EA

1

Norway

1

ME

1

New Zealand

1

Korea, Republic of

1

Peru

1

Israel

1

Mexico

1

Australia

1

Bulgaria

1

South Africa

1

Colombia

1

Egypt

1

Tunisia

1

Slovenia

1

Hungary

15. List of Lusedra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6204257 EISAI INC Water soluble prodrugs of hindered alcohols
Jul, 2022

(10 months ago)

Do you want to check out LUSEDRA patents from before 2022?

Drugs and Companies using FOSPROPOFOL DISODIUM ingredient

Market Authorisation Date: 12 December, 2008

Treatment: Sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedation

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

16. List of Macrilen drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6861409 NOVO Growth hormone secretagogues
Aug, 2022

(9 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719 NOVO Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Oct, 2027

(4 years from now)

Do you want to check out MACRILEN patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 20, 2024

Drugs and Companies using MACIMORELIN ACETATE ingredient

Market Authorisation Date: 20 December, 2017

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

MACRILEN family patents

5

United States

5

European Union

4

Spain

4

Denmark

3

Austria

3

Hong Kong

3

Germany

3

Japan

3

Cyprus

3

Portugal

3

Bulgaria

2

Czech Republic

2

Poland

2

China

2

Taiwan

2

Australia

2

United Kingdom

1

Russia

1

Brazil

1

Canada

1

Ukraine

1

Argentina

1

Norway

1

New Zealand

1

Korea, Republic of

1

Israel

1

Slovenia

1

Mexico

1

Netherlands

1

South Africa

1

Slovakia

1

Hungary

17. List of Saxenda drug patents

SAXENDA's oppositions filed in EPO
SAXENDA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343 NOVO Derivatives of GLP-1 analogs
Aug, 2022

(9 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7762994

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(1 year, 5 months from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions
Jul, 2037

(14 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(3 years from now)

US8846618 NOVO Stable formulation of modified GLP-1
Jun, 2022

(11 months ago)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(3 years from now)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(11 months from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US9968659 NOVO Liraglutide in cardiovascular conditions
Jan, 2037

(13 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(8 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(4 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 4 months ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(29 days from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(3 years from now)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 4 months ago)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(3 years from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(3 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(3 years from now)

US8920383

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(3 years from now)

US8846618

(Pediatric)

NOVO Stable formulation of modified GLP-1
Dec, 2022

(5 months ago)

USRE46363

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Feb, 2027

(3 years from now)

US9457154

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Mar, 2028

(4 years from now)

US9687611

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Aug, 2027

(4 years from now)

US9861757

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Jul, 2026

(3 years from now)

US9616180

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(3 years from now)

US9775953

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(3 years from now)

US9108002

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(3 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Aug, 2032

(9 years from now)

US9486588

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(10 months ago)

US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs
Feb, 2023

(3 months ago)

US8672898

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(10 months ago)

US8114833

(Pediatric)

NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Feb, 2026

(2 years from now)

US6899699

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(10 months ago)

US8684969

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Apr, 2026

(2 years from now)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(6 months from now)

US10220155

(Pediatric)

NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jan, 2027

(3 years from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

Do you want to check out SAXENDA patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 4, 2023

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's patent expiration?
More Information on Dosage

SAXENDA family patents

57

United States

28

Denmark

28

European Union

15

Japan

13

Spain

13

China

10

Poland

9

Australia

8

Russia

8

Canada

7

Austria

7

Germany

6

Brazil

6

Portugal

3

Korea, Republic of

3

Slovenia

3

Hungary

2

Mexico

2

South Africa

1

Hong Kong

1

Philippines

1

Turkey

1

RS

1

Morocco

1

Croatia

1

Cyprus

1

Israel

1

Chile

18. List of Teflaro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6417175 ALLERGAN Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Apr, 2022

(1 year, 1 month ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8247400 ALLERGAN Cephem compounds useful for the treatment of bacterial infections
Feb, 2031

(7 years from now)

US9629861 ALLERGAN Compositions and methods for treating bacterial infections using ceftaroline
Sep, 2030

(7 years from now)

Do you want to check out TEFLARO patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Sep 13, 2022

Drugs and Companies using CEFTAROLINE FOSAMIL ingredient

Market Authorisation Date: 29 October, 2010

Treatment: Method of treating bacterial infections; Methods for treating bacterial infections

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of TEFLARO before it's patent expiration?
More Information on Dosage

TEFLARO family patents

8

United States

3

New Zealand

2

Canada

2

Peru

2

Mexico

1

Dominican Republic

1

China

1

Brazil

1

Ukraine

1

Singapore

EA

1

EA

1

Nicaragua

1

Honduras

1

Korea, Republic of

1

Guatemala

1

Chile

1

Australia

1

Cuba

1

Costa Rica

1

Ecuador

1

South Africa

1

Colombia

1

European Union

19. List of Toviaz drug patents

TOVIAZ Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6858650 PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jul, 2022

(10 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8088398 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(4 years from now)

US7807715 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(4 years from now)

US8501723 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(4 years from now)

US6858650

(Pediatric)

PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jan, 2023

(4 months ago)

US7807715

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(4 years from now)

US8088398

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(4 years from now)

US8501723

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(4 years from now)

Do you want to check out TOVIAZ patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Jun 17, 2024
Pediatric Exclusivity (PED) Dec 17, 2024

Drugs and Companies using FESOTERODINE FUMARATE ingredient

Market Authorisation Date: 31 October, 2008

Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TOVIAZ before it's patent expiration?
More Information on Dosage

TOVIAZ family patents

6

United States

20. List of Velcade drug patents

VELCADE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6958319 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(1 year, 4 months ago)

US6713446 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(1 year, 4 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6713446

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(10 months ago)

US6958319

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(10 months ago)

Do you want to check out VELCADE patents from before 2022?
Exclusivity Exclusivity Expiration
Pediatric Exclusivity (PED) Apr 8, 2022

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 13 May, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

How can I launch a generic of VELCADE before it's patent expiration?
More Information on Dosage

VELCADE family patents

9

United States

4

European Union

3

Spain

3

Cyprus

3

Denmark

2

Canada

2

Portugal

2

Japan

1

Germany

1

Hong Kong

1

Austria

1

Turkey

1

Australia

21. List of Venlafaxine Besylate drug patents

VENLAFAXINE BESYLATE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6717015 ALMATICA Venlafaxine besylate
Mar, 2023

(2 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776358 ALMATICA Extended release venlafaxine besylate tablets
May, 2028

(4 years from now)

Do you want to check out VENLAFAXINE BESYLATE patents from before 2022?

Drugs and Companies using VENLAFAXINE BESYLATE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Treatment of depression and generalized anxiety disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

VENLAFAXINE BESYLATE family patents

4

United States

2

European Union

1

South Africa

1

Argentina

1

Australia

22. List of Viibryd drug patents

VIIBRYD Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7834020 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(11 months ago)

US8673921 ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(11 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236804 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Jun, 2022

(11 months ago)

US8193195 ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(11 months ago)

US7834020

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(5 months ago)

US8193195

(Pediatric)

ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(5 months ago)

US8236804

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Dec, 2022

(5 months ago)

US8673921

(Pediatric)

ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(5 months ago)

Do you want to check out VIIBRYD patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Jan 31, 2023
Pediatric Exclusivity (PED) Jul 31, 2023

Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 January, 2011

Treatment: Treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

How can I launch a generic of VIIBRYD before it's patent expiration?
More Information on Dosage

VIIBRYD family patents

16

Canada

15

United States

3

Japan

3

European Union

2

Hong Kong

2

Czech Republic

2

China

2

Slovakia

1

Spain

1

Austria

1

Malaysia

1

Denmark

1

Germany

1

Poland

1

Russia

1

Brazil

1

Estonia

1

Ukraine

1

Argentina

1

New Zealand

1

Korea, Republic of

1

Cyprus

1

Israel

1

Portugal

1

Mexico

1

Australia

1

Ecuador

1

South Africa

1

Hungary

23. List of Vimpat drug patents

VIMPAT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE38551 UCB INC Anticonvulsant enantiomeric amino acid derivatives
Mar, 2022

(1 year, 2 months ago)

Do you want to check out VIMPAT patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Nov 16, 2023
New Patient Population (NPP) Oct 14, 2024

Drugs and Companies using LACOSAMIDE ingredient

Market Authorisation Date: 28 October, 2008

Treatment: Method of treating partial onset seizures in patients 4 years of age and older; Method of treating, as initial loading dose for monotherapy or adjunctive therapy, partial onset-seizures in a patient w...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of VIMPAT before it's patent expiration?
More Information on Dosage

24. List of Vyvanse drug patents

VYVANSE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7659253 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7655630 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7662787 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(3 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7659254 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7671030 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7723305 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7718619 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7662788 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7713936 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7678771 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7678770 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7674774 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7687467 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7105486 TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Feb, 2023

(3 months ago)

US7671031 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7223735 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(3 months ago)

US7700561 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7687466 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(3 months ago)

US7718619

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(2 months from now)

US7223735

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(2 months from now)

US7655630

(Pediatric)